Circulation Research. 2003;92:1193-1200
Published online before print May 15, 2003, doi: 10.1161/01.RES.0000076889.23082.F1
Published online before print May 15, 2003, doi: 10.1161/01.RES.0000076889.23082.F1
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Molecular Medicine |
Genetically Determined Heterogeneity in Hemoglobin Scavenging and Susceptibility to Diabetic Cardiovascular Disease
From the Technion Faculty of Medicine, Technion-Israel Institute of Technology and Rambam Medical Center, Haifa, Israel.
Correspondence to Andrew P. Levy, Technion Faculty of Medicine, POB 9649, Haifa, Israel. E-mail alevy{at}tx.technion.ac.il
A major function of haptoglobin (Hp) is to bind hemoglobin (Hb) to form a stable Hp-Hb complex and thereby prevent Hb-induced oxidative tissue damage. Clearance of the Hp-Hb complex can be mediated by the monocyte/macrophage scavenger receptor CD163. We recently demonstrated that diabetic individuals homozygous for the Hp 2 allele (Hp 2-2) were at 500% greater risk of cardiovascular disease (CVD) compared with diabetic individuals homozygous for the Hp 1 allele (Hp 1-1). No differences in risk by Hp type were seen in individuals without diabetes. To understand the relationship between the Hp polymorphism and diabetic CVD, we sought to identify differences in antioxidant and scavenging functions between the Hp types and to determine how these functions were modified in diabetes. The scavenging function of Hp was assessed using rhodamine-tagged and 125I-Hp in cell lines stably transfected with CD163 and in macrophages expressing endogenous CD163. We found that the rate of clearance of Hp 1-1–Hb by CD163 is markedly greater than that of Hp 2-2–Hb. Diabetes is associated with an increase in the nonenzymatic glycosylation of serum proteins, including Hb. The antioxidant function of Hp was assessed with glycosylated and nonglycosylated Hb. We identified a severe impairment in the ability of Hp to prevent oxidation mediated by glycosylated Hb. We propose that the specific interaction between diabetes, CVD, and Hp genotype is the result of the heightened urgency of rapidly clearing glycosylated Hb-Hp complexes from the subendothelial space before they can oxidatively modify low-density lipoprotein to atherogenic oxidized low-density lipoprotein.
Key Words: cardiovascular disease • diabetes • hemoglobin • haptoglobin • scavenger receptor
This article has been cited by other articles:
 |
|
 |
|
  T. Costacou, R. E. Ferrell, D. Ellis, and T. J. Orchard Haptoglobin Genotype and Renal Function Decline in Type 1 Diabetes Diabetes, December 1, 2009; 58(12): 2904 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kapralov, I. I. Vlasova, W. Feng, A. Maeda, K. Walson, V. A. Tyurin, Z. Huang, R. K. Aneja, J. Carcillo, H. Bayir, et al. Peroxidase Activity of Hemoglobin{middle dot}Haptoglobin Complexes: COVALENT AGGREGATION AND OXIDATIVE STRESS IN PLASMA AND MACROPHAGES J. Biol. Chem., October 30, 2009; 284(44): 30395 - 30407. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tripathi, K. M. Lammers, S. Goldblum, T. Shea-Donohue, S. Netzel-Arnett, M. S. Buzza, T. M. Antalis, S. N. Vogel, A. Zhao, S. Yang, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2 PNAS, September 29, 2009; 106(39): 16799 - 16804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Nielsen and S. K. Moestrup Receptor targeting of hemoglobin mediated by the haptoglobins: roles beyond heme scavenging Blood, July 23, 2009; 114(4): 764 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, J. Sanz, and V. Fuster Promoting Mechanisms of Vascular Health: Circulating Progenitor Cells, Angiogenesis, and Reverse Cholesterol Transport J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2315 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bhatia, J. L. Hallock, A. Dutta, S. Karkashon, L. S. Sterner, T. Miyazaki, A. Dean, and J. A. Little Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells Blood, June 18, 2009; 113(25): 6440 - 6448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Nakhoul, R. Miller-Lotan, H. Awad, R. Asleh, K. Jad, N. Nakhoul, R. Asaf, N. Abu-Saleh, and A. P. Levy Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus Am J Physiol Renal Physiol, April 1, 2009; 296(4): F830 - F838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asleh, S. Blum, S. Kalet-Litman, J. Alshiek, R. Miller-Lotan, R. Asaf, W. Rock, M. Aviram, U. Milman, C. Shapira, et al. Correction of HDL Dysfunction in Individuals With Diabetes and the Haptoglobin 2-2 Genotype Diabetes, October 1, 2008; 57(10): 2794 - 2800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. R. Moreno, K. R. Purushothaman, M. Purushothaman, P. Muntner, N. S. Levy, V. Fuster, J. T. Fallon, P. A. Lento, A. Winterstern, and A. P. Levy Haptoglobin Genotype Is a Major Determinant of the Amount of Iron in the Human Atherosclerotic Plaque J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1049 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Costacou, R. E. Ferrell, and T. J. Orchard Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes Diabetes, June 1, 2008; 57(6): 1702 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Milman, S. Blum, C. Shapira, D. Aronson, R. Miller-Lotan, Y. Anbinder, J. Alshiek, L. Bennett, M. Kostenko, M. Landau, et al. Vitamin E Supplementation Reduces Cardiovascular Events in a Subgroup of Middle-Aged Individuals With Both Type 2 Diabetes Mellitus and the Haptoglobin 2-2 Genotype: A Prospective Double-Blinded Clinical Trial Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 341 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Chaichana, A. P. Levy, R. Miller-Lotan, S. Shakur, and R. J. Tamargo Haptoglobin 2-2 Genotype Determines Chronic Vasospasm After Experimental Subarachnoid Hemorrhage Stroke, December 1, 2007; 38(12): 3266 - 3271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. l. Sullivan Macrophage Iron, Hepcidin, and Atherosclerotic Plaque Stability Experimental Biology and Medicine, September 1, 2007; 232(8): 1014 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Levy, K. R. Purushothaman, N. S. Levy, M. Purushothaman, M. Strauss, R. Asleh, S. Marsh, O. Cohen, S. K. Moestrup, H. J. Moller, et al. Downregulation of the Hemoglobin Scavenger Receptor in Individuals With Diabetes and the Hp 2-2 Genotype: Implications for the Response to Intraplaque Hemorrhage and Plaque Vulnerability Circ. Res., July 6, 2007; 101(1): 106 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Schaer, F. Vallelian, A. Imhof, G. Schoedon, and D. J. Schaer CD163-expressing monocytes constitute an endotoxin-sensitive Hb clearance compartment within the vascular system J. Leukoc. Biol., July 1, 2007; 82(1): 106 - 110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Blum, R. Asaf, J. Guetta, R. Miller-Lotan, R. Asleh, R. Kremer, N. S. Levy, F. G. Berger, D. Aronson, X. Fu, et al. Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice J. Am. Coll. Cardiol., January 2, 2007; 49(1): 82 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Levy, J. E. Levy, S. Kalet-Litman, R. Miller-Lotan, N. S. Levy, R. Asaf, J. Guetta, C. Yang, K. R. Purushothaman, V. Fuster, et al. Haptoglobin Genotype Is a Determinant of Iron, Lipid Peroxidation, and Macrophage Accumulation in the Atherosclerotic Plaque Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 134 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asleh, R. Miller-Lotan, M. Aviram, T. Hayek, M. Yulish, J. E. Levy, B. Miller, S. Blum, U. Milman, C. Shapira, et al. Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo Circ. Res., December 8, 2006; 99(12): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moreno, K-R. Purushothaman, M. Sirol, A. P. Levy, and V. Fuster Neovascularization in Human Atherosclerosis Circulation, May 9, 2006; 113(18): 2245 - 2252. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Borsody, A. Burke, W. Coplin, R. Miller-Lotan, and A. Levy Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage Neurology, March 14, 2006; 66(5): 634 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Schaer, C. A. Schaer, P. W. Buehler, R. A. Boykins, G. Schoedon, A. I. Alayash, and A. Schaffner CD163 is the macrophage scavenger receptor for native and chemically modified hemoglobins in the absence of haptoglobin Blood, January 1, 2006; 107(1): 373 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suleiman, D. Aronson, R. Asleh, M. R. Kapeliovich, A. Roguin, S. R. Meisel, M. Shochat, A. Sulieman, S. A. Reisner, W. Markiewicz, et al. Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients With Diabetes and Acute Myocardial Infarction Diabetes, September 1, 2005; 54(9): 2802 - 2806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Asleh, J. Guetta, S. Kalet-Litman, R. Miller-Lotan, and A. P. Levy Haptoglobin Genotype- and Diabetes-Dependent Differences in Iron-Mediated Oxidative Stress In Vitro and In Vivo Circ. Res., March 4, 2005; 96(4): 435 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Greaves and S. Gordon Thematic review series: The Immune System and Atherogenesis. Recent insights into the biology of macrophage scavenger receptors J. Lipid Res., January 1, 2005; 46(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Levy, H. C. Gerstein, R. Miller-Lotan, R. Ratner, M. McQueen, E. Lonn, and J. Pogue The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes Diabetes Care, November 1, 2004; 27(11): 2767 - 2767. [Full Text] [PDF]
|
|
|
|
 |
|
 N. S. Levy and A. P. Levy ELISA for Determination of the Haptoglobin Phenotype Clin. Chem., November 1, 2004; 50(11): 2148 - 2150. [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, J. E. Tanus-Santos, C. D. Reiter, A. Dejam, S. Shiva, R. D. Smith, N. Hogg, and M. T. Gladwin Biological activity of nitric oxide in the plasmatic compartment PNAS, August 3, 2004; 101(31): 11477 - 11482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Sulahian, P. A. Pioli, K. Wardwell, and P. M. Guyre Cross-linking of Fc{gamma}R triggers shedding of the hemoglobin-haptoglobin scavenger receptor CD163 J. Leukoc. Biol., July 1, 2004; 76(1): 271 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Levy, P. Friedenberg, R. Lotan, P. Ouyang, M. Tripputi, L. Higginson, F. R. Cobb, J.-C. Tardif, V. Bittner, and B. V. Howard The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women Diabetes Care, April 1, 2004; 27(4): 925 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Philippidis, J.C. Mason, B.J. Evans, I. Nadra, K.M. Taylor, D.O. Haskard, and R.C. Landis Hemoglobin Scavenger Receptor CD163 Mediates Interleukin-10 Release and Heme Oxygenase-1 Synthesis: Antiinflammatory Monocyte-Macrophage Responses In Vitro, in Resolving Skin Blisters In Vivo, and After Cardiopulmonary Bypass Surgery Circ. Res., January 9, 2004; 94(1): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Roguin, W. Koch, A. Kastrati, D. Aronson, A. Schomig, and A. P. Levy Haptoglobin Genotype Is Predictive of Major Adverse Cardiac Events in the 1-Year Period After Percutaneous Transluminal Coronary Angioplasty in Individuals With Diabetes Diabetes Care, September 1, 2003; 26(9): 2628 - 2631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suleiman, M. R. Kapeliovich, A. Roguin, D. Aronson, S. R. Meisel, M. Shochat, S. A. Reisner, H. Hammerman, R. Lotan, N. S. Levy, et al. Haptoglobin Type and 30-Day Mortality in Diabetic Individuals Presenting With Acute Myocardial Infarction Diabetes Care, September 1, 2003; 26(9): 2699 - 2700. [Full Text] [PDF]
|
|